Search Results

You are looking at 1 - 10 of 178 items for :

  • Refine by Access: All x
Clear All
Full access

Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report

Eugene R. Przespolewski, Jeffrey Baron, Farshid Kashef, Kai Fu, Sheila N. Jani Sait, Francisco Hernandez-Ilizaliturri, and James Thompson

management of chronic myeloid leukemia (CML) has led to significant improvement in outcomes. These TKIs (eg, imatinib, dasatinib, nilotinib, bosutinib) have transformed CML from a fatal malignancy to a chronic disease with which most patients achieve a normal

Full access

Using Imatinib as Neoadjuvant Therapy in Dermatofibrosarcoma Protuberans: Potential Pluses and Minuses

Hillary Johnson-Jahangir, William Sherman, and Désirée Ratner

, with en face margin evaluation performed using complete circumferential peripheral and deep margin assessment. 9 – 14 However, in surgically difficult cases, complete excision may result in cosmetic deformity or functional disability. Using imatinib

Full access

Response Monitoring, Tolerability, and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen, and Diana I. Brixner

Imatinib became the front-line treatment for patients with chronic-phase chronic myelogenous leukemia (CP-CML) based on results from the International Randomized Study of Interferon and STI571 (IRIS), which compared imatinib versus interferon

Full access

Resistance to Imatinib: Mechanisms and Management

Michael Deininger

References 1 Hughes TP Kaeda J Branford S . Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia . N Engl J Med 2003 ; 349 : 1423 – 1432 . 2

Full access

Issues of Imatinib and Pregnancy Outcome

Jane Apperley

target of the TKI; imatinib inhibits not only Abl but also c-kit, platelet-derived growth factor receptors α and β (PDGFR-α/β), ARG, and c-FMS. Dasatinib, a second-generation TKI, also inhibits Src and related proteins. Several of these proteins are known

Full access

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz, and Meir Wetzler

years, and eventually leads to terminal blast-phase disease, with death occurring from bleeding and infectious complications. 3 First-Line Treatment: Imatinib Versus Second-Generation Tyrosine Kinase Inhibitors Imatinib Imatinib is a selective inhibitor

Full access

Imatinib-Induced Bone Edema: Case Report and Review of Literature

Lucas Vieira dos Santos, João Paulo Lima, Kathia Cristina Abdalla, Arinilda Campos Bragagnoli, Florinda Almeida Santos, Alexandre dos Anjos Jácome, and Fabiano Elias Porto

imatinib Distinguish between the signs and symptoms of bone pain associated with imatinib therapy versus bone metastasis in patients with GISTs Background Gastrointestinal stromal tumors (GISTs) are the most common nonepithelial cancers of the

Full access

NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

for GISTs rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib). Because of these changes, the NCCN organized a multidisciplinary panel composed of experts in medical oncology, molecular

Full access

Neoadjuvant Imatinib for Borderline Resectable GIST

M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz

consideration of neoadjuvant imatinib with the hope of shrinking the tumor enough to facilitate duodenectomy rather than requiring a Whipple pancreaticoduodenectomy. Her past medical and surgical history was significant for a complicated appendectomy requiring

Full access

Online Pharmacy Accessibility of Imatinib, An Oral Chemotherapy Medication

Yujiao Sun, Adam Hendrix, Benyam Muluneh, and Sachiko Ozawa

treatable chronic condition with extended life expectancy. 2 Despite the clinical benefits, the cost of TKIs continues to be a significant barrier to access because most patients need to take imatinib indefinitely. 3 – 5 Generic imatinib (Gleevec), the